Study Summary
This trial will study if a new drug is effective and safe in treating inflammation in sarcopenia/frailty, which are age-related conditions.
- Pre-Frail or Frail State
- Geriatric Frailty Syndrome
- Frailty
- Frailty Syndrome
- Aging
- Sarcopenia
- Preoperative Frailty
- Debilitated States
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
3 Primary · 1 Secondary · Reporting Duration: Day 28 (8-24 hours post dose)
Trial Safety
Phase-Based Safety
Trial Design
8 Treatment Groups
Cohort 4: MYMD1 1050mg
1 of 8
Cohort 1: MYMD1 600mg
1 of 8
Cohort 3: MYMD1 900mg
1 of 8
Cohort 2: MYMD1 750mg
1 of 8
Cohort 2: Placebo 750mg
1 of 8
Cohort 1: Placebo 600mg
1 of 8
Cohort 3: Placebo 900mg
1 of 8
Cohort 4: Placebo group 1050mg
1 of 8
Active Control
Experimental Treatment
Non-Treatment Group
40 Total Participants · 8 Treatment Groups
Primary Treatment: MYMD-1 600MG · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 65 - 99 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| New Jersey | 33.3% |
| Florida | 33.3% |
| Texas | 33.3% |
How old are they?
| 65+ | 100.0% |
What site did they apply to?
| Clinical Research of West Florida | 50.0% |
| Johns Hopkins Bayview Medical Center | 50.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 50.0% |
| Did not meet criteria | 50.0% |
How responsive is this trial?
Typically responds via
| 100.0% | |
Frequently Asked Questions
Does MYMD-1 600MG pose any risks to its users?
"Our team at Power has assessed the safety of MYMD-1 600MG as a 2, due to there being clinical evidence that suggests it is secure but no documents indicating its efficacy." - Anonymous Online Contributor
Are there any remaining vacancies in this trial that patients can join?
"This ongoing research is on the lookout for qualified participants. The listing to clinicaltrials.gov was first posted on February 1st 2022 and most recently edited March 30th of the same year." - Anonymous Online Contributor
How many individuals are engaged in this clinical trial?
"Affirmative. Clinicaltrials.gov hosts information that confirms the active recruitment process for this medical experiment, which was originally posted on February 1st 2022 and recently modified on March 30th 2022. This study requires 40 participants to be recruited across 3 distinct sites." - Anonymous Online Contributor
May I participate in this medical research project?
"Forty elderly individuals diagnosed with sarcopenia aged between 65 and 99 are being admitted to this trial. To be considered, applicants must satisfy the following conditions: a minimum age of 65 years at the time of signing their informed consent form; elevated biomarkers of inflammation (IL-6 ≥2.5 pg/mL or sTNFR1 ≥1500 pg/mL); low gait speed ≤0.8 m/s; Short Physical Performance Battery score ≤ 8 points; weight over 35 kg; adequate dietary intake; able to complete a 4 meter timed walk; assessment and documentation of sarcopenia-related muscle mass loss determined by Dual" - Anonymous Online Contributor
Are applicants over 30 years of age eligible for participation in this trial?
"The required age range for this trial is 65 to 99, with 35 studies targeting patients younger than 18 and 703 trials focusing on the elderly." - Anonymous Online Contributor